Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
1.090
+0.100 (10.10%)
At close: Dec 20, 2024, 4:00 PM
1.050
-0.040 (-3.67%)
After-hours: Dec 20, 2024, 6:13 PM EST
Plus Therapeutics Employees
Plus Therapeutics had 20 employees as of December 31, 2023. The number of employees increased by 3 or 17.65% compared to the previous year.
Employees
20
Change (1Y)
3
Growth (1Y)
17.65%
Revenue / Employee
$286,250
Profits / Employee
-$644,250
Market Cap
6.43M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Syra Health | 162 |
PAVmed | 107 |
Kindly MD | 65 |
Ainos | 46 |
ABVC BioPharma | 19 |
Galecto | 13 |
Portage Biotech | 7 |
CNS Pharmaceuticals | 5 |
PSTV News
- 4 days ago - Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium - GlobeNewsWire
- 17 days ago - Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium - GlobeNewsWire
- 18 days ago - Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply - GlobeNewsWire
- 26 days ago - Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference - GlobeNewsWire
- 4 weeks ago - Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases - GlobeNewsWire
- 4 weeks ago - Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases - GlobeNewsWire
- 5 weeks ago - Plus Therapeutics, Inc. (PSTV) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire